SABCS 2025: Studienergebnisse bei frühem HER2-positivem Brustkrebs

In this report from the SABCS (San Antonio Breast Cancer Symposium), Prof. Dr. Marc Thill from the Agaplesion Markus Hospital in Frankfurt and patient representative Alexandra von Korff from Patients Today explain current study results on early HER2-positive breast cancer. For example, the DESTINY-Breast11 study compares T-DXd with standard pre-operative therapy in terms of tolerability. Furthermore, the experts discuss the DESTINY-Breast05 study in the video. This study targets patients with HER2-positive breast cancer who still have detectable tumor remnants after initial treatment (e.g., pre-operative chemotherapy) and who have an increased risk of recurrence. The study compares the two drugs trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1), which are administered after the first phase of therapy. Side effects and various safety aspects are discussed, among other things. . ... More information about breast cancer can always be found at https://mammamia-online.de. Coverage of the San Antonio Breast Cancer Symposium (SABCS) is provided by Patients Today (https://patientstoday.de/) and is made possible with the kind support of Lilly and AstraZeneca.